indacaterol   Click here for help

GtoPdb Ligand ID: 7455

Synonyms: Arcapta Neohaler® | Onbrez® | QAB-149 | QAB149
Approved drug Immunopharmacology Ligand
indacaterol is an approved drug (EMA (2009), FDA (2011))
Compound class: Synthetic organic
Comment: Only the R-enantiomer, as the maleate salt (PubChem CID 9827599) is contained in the medicinal product.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 85.35
Molecular weight 392.21
XLogP 4.65
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCc1cc2CC(Cc2cc1CC)NCC(c1ccc(c2c1ccc(=O)[nH]2)O)O
Isomeric SMILES CCc1cc2CC(Cc2cc1CC)NC[C@@H](c1ccc(c2c1ccc(=O)[nH]2)O)O
InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
InChI Key QZZUEBNBZAPZLX-QFIPXVFZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Aparici M, Gómez-Angelats M, Vilella D, Otal R, Carcasona C, Viñals M, Ramos I, Gavaldà A, De Alba J, Gras J et al.. (2012)
Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
J Pharmacol Exp Ther, 342 (2): 497-509. [PMID:22588259]
2. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L et al.. (2006)
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
J Pharmacol Exp Ther, 317 (2): 762-70. [PMID:16434564]
3. Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D et al.. (2012)
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Bioorg Med Chem Lett, 22 (19): 6280-5. [PMID:22932315]
4. Cazzola M, Matera MG, Lötvall J. (2005)
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.
Expert Opin Investig Drugs, 14 (7): 775-83. [PMID:16022567]
5. Proudman RGW, Baker JG. (2025)
A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD.
Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869]
6. Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, Knowles RG. (2013)
In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
J Pharmacol Exp Ther, 344 (1): 218-30. [PMID:23131596]